|
| Press Releases |
|
 |
|
| Monday, March 13, 2023 |
|
|
歐康維視獲納入滬港通及深港通名單 |
| 中國領先眼科醫藥平台公司 — 歐康維視生物（「歐康維視」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1477）欣然宣佈，集團在香港聯合交易所有限公司（「香港交易所」）發行的普通股正式被納入港股通下滬港通及深港通股票名單，並於3月13日起生效。 more info >> |
|
|
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023. more info >> |
|
| Tuesday, February 14, 2023 |
|
|
欧康维视发布2022年度业绩盈利预喜 |
| 中国眼科医药平台公司 — 欧康维视生物（「欧康维视」或「公司」，连同其附属公司，统称「集团」，股份代号：1477）欣然宣布，预期截至2022年12月31日止年度（「2022年度」）之总收入及毛利分别同比大幅增长。 more info >> |
|
|
歐康維視發佈2022年度業績盈利預喜 |
| 中國眼科醫藥平台公司 — 歐康維視生物（「歐康維視」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1477）欣然宣佈，預期截至2022年12月31日止年度（「2022年度」）之總收入及毛利分別同比大幅增長。 more info >> |
|
|
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022"). more info >> |
|
| Friday, February 3, 2023 |
|
|
欧康维视研发的治疗干眼症的I类新药OT-202 I期临床试验完成 |
| 中国眼科医药平台公司 — 欧康维视生物（「欧康维视」或「公司」，连同其附属公司，统称「集团」，股份代号：1477）宣布，其研发的治疗干眼症的I类新药OT-202（酪氨酸激酶抑制剂）的I期临床试验已经顺利完成。 more info >> |
|
|
歐康維視研發的治療乾眼症的I類新藥OT-202 I期臨床試驗完成 |
| 中國眼科醫藥平台公司 — 歐康維視生物（「歐康維視」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1477）宣佈，其研發的治療乾眼症的I類新藥OT-202（酪氨酸激酶抑制劑）的I期臨床試驗已經順利完成。 more info >> |
|
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully. more info >> |
|
| Wednesday, February 1, 2023 |
|
|
欧康维视自研新药OT-101于中国完成完成受试者入组 |
| 中国眼科医药平台公司 — 欧康维视生物（「欧康维视」或「公司」，连同其附属公司，统称「集团」，股份代号：1477）宣布，治疗儿童近视发展的自研新药OT-101（0.01%硫酸阿托品滴眼液）已于本年1月18日完成在中国的170名受试者的全球III期随机、双盲、安慰剂对照、平行组、多中心临床试验入组。 more info >> |
|
|
歐康維視自研新藥OT-101於中國完成完成受試者入組 |
| 中國眼科醫藥平台公司 — 歐康維視生物（「歐康維視」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1477）宣佈，治療兒童近視發展的自研新藥OT-101（0.01%硫酸阿托品滴眼液）已於本年1月18日完成在中國的170名受試者的全球III期隨機、雙盲、安慰劑對照、平行組、多中心臨床試驗入組。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
mRNA腫瘤疫苗五年數據印證療效 雲頂新耀搶跑國內個性化腫瘤疫苗賽道
Jan 21, 2026 19:00 HKT/SGT
|
|
|
mRNA肿瘤疫苗五年数据印证疗效 云顶新耀抢跑国内个性化肿瘤疫苗赛道
Jan 21, 2026 19:00 HKT/SGT
|
|
|
Honda to Discontinue Production of Fuel Cell Systems at Fuel Cell System Manufacturing LLC in the U.S.
Jan 21, 2026 17:44 JST
|
|
|
Notice regarding the dissolution of the joint venture in the home elevator business
Jan 21, 2026 17:04 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 21, 2026 16:44 JST
|
|
|
MHI and ITB Deepen Research Collaboration on Ammonia-Based Clean Power in Indonesia
Jan 21, 2026 16:37 JST
|
|
|
Asian Financial Forum opens next Monday with a fresh perspective and new tagline, Finance Empowering Business
Jan 21, 2026 14:30 JST
|
|
|
Exito Drives India's Digital-First Revolution with the Flagship 43rd Digital Transformation Summit - India 2026
Jan 21, 2026 13:00 HKT/SGT
|
|
|
MHI-TCが「自走式舶用旅客搭乗橋」を横浜市に納入、1月13日に供用開始
Jan 21, 2026 11:55: JST
|
|
|
MHI-TC Delivers Self-Propelled Mobile Seaport Passenger Boarding Bridge to Yokohama City, Entering Service on January 13th
Jan 21, 2026 11:02 JST
|
|
|
Dowway Proposes Rebranding with a New Name 'Defeng Solife'
Jan 21, 2026 09:51 HKT/SGT
|
|
|
天平道合擬煥新改名為「德豐宿來」
Jan 21, 2026 09:39 HKT/SGT
|
|
|
天平道合拟焕新改名为"德丰宿来"
Jan 21, 2026 09:19 HKT/SGT
|
|
|
通用原子航空系統公司與Calidus簽署諒解備忘錄 合作生產MQ-9B與Gambit協同作戰飛機
Jan 21, 2026 05:00 HKT/SGT
|
|
|
通用原子航空系统公司与Calidus签署谅解备忘录 合作生产MQ-9B与Gambit协同作战飞机
Jan 21, 2026 05:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
